carboxyamidotriazole Report issue

Small molecule Experimental
AACT DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Carboxyamidotriazole is a calcium channel blocker that blocks voltage-gated and ligand-gated calcium channels and has been investigated as an anti-cancer drug in vitro.   Wikipedia

Chemistry

More Chemistry

Pharmacology

Alternative names

1h-1,2,3-triazole-4-carboxamide, 5-amino-1-((3,5-dichloro-4-(4-chlorobenzoyl)phenyl)methyl)- | 4-cai | cai | carboxyamidotriazole | carboxyamido-triazole | l651582 | l 651582 | l-651582

Organizations (7)

Research & Development (7)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (15)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (15)


 

Brain Neoplasms (Phase 1)

Breast Neoplasms (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Renal Cell (Phase 2)

Fallopian Tube Neoplasms (Phase 2)

Glioblastoma (Phase 2)

Gliosarcoma (Phase 2)

Hamartoma (Phase 2)

Intestinal Neoplasms (Phase 1)

Kidney Neoplasms (Phase 2)

Lung Neoplasms (Phase 1)

Lymphoma (Phase 1)

Melanoma (Phase 1)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial Organizations: 7

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue